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Abstract
Background
Multiple micronutrients (MMN) are commonly prescribed in pediatric primary healthcare in
sub-Saharan Africa to improve nutritional status and appetite without evidence for their
effectiveness or international clinical guidelines. Community-wide MMN supplementation
has shown limited and heterogeneous impact on growth and morbidity. Short-term ready-to-
use therapeutic foods in acutely sick children in a hospital setting also had limited efficacy
regarding subsequent growth. The effectiveness of MMN in improving morbidity or growth in
sick children presenting for primary care has not been assessed.
Methods and findings
We undertook a double-blind randomised controlled trial of small-quantity lipid-based nutri-
ent supplements (SQ-LNS) fortified with 23 micronutrients in children aged 6 months (mo)
to 5 years (y) presenting with an illness at a rural primary healthcare centre in The Gambia.
Primary outcomes were repeat clinic presentations and growth over 24 wk. Participants
were randomly assigned to receive 1 of 3 interventions: (1) supplementation with micronutri-
ent-fortified SQ-LNS for 12 wk (MMN-12), (2) supplementation with micronutrient-fortified
SQ-LNS for 6 wk followed by unfortified SQ-LNS for 6 wk (MMN-6), or (3) supplementation
with unfortified SQ-LNS for 12 wk (MMN-0) to be consumed in daily portions. Treatment
masking used 16 letters per 6-wk block in the randomisation process. Blinded intention-to-
treat analysis based on a prespecified statistical analysis plan included all participants eligi-
ble and correctly enrolled.
Between December 2009 and June 2011, 1,101 children (age 6–60 mo, mean 25.5 mo)
were enrolled, and 1,085 were assessed (MMN-0 = 361, MMN-6 = 362, MMN-12 = 362).
MMN supplementation was associated with a small increase in height-for-age z-scores 24
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wk after recruitment (effect size for MMN groups combined: 0.084 SD/24 wk, 95% CI: 0.005,
0.168; p = 0.037; equivalent to 2–5 mm depending on age). No significant difference in fre-
quency of morbidity measured by the number of visits to the clinic within 24 wk follow-up
was detected with 0.09 presentations per wk for all groups (MMN-0 versus MMN-6: adjusted
incidence rate ratio [IRR] 1.03, 95% CI: 0.92, 1.16; MMN-0 versus MMN-12: 1.05, 95% CI:
0.93, 1.18). In post hoc analysis, clinic visits significantly increased by 43% over the first 3
wk of fortified versus unfortified SQ-LNS (adjusted IRR 1.43; 95% CI: 1.07, 1.92; p = 0.016),
with respiratory presentations increasing by 52% with fortified SQ-LNS (adjusted IRR 1.52;
95% CI: 1.01, 2.30; p = 0.046). The number of severe adverse events during supplementa-
tion were similar between groups (MMN-0 = 20 [1 death]; MMN-6 = 21 [1 death]; MMN-12 =
20 [0 death]). No participant withdrew due to adverse effects. Study limitations included the
lack of supervision of daily supplementation.
Conclusion
Prescribing micronutrient-fortified SQ-LNS to ill children presenting for primary care in rural
Gambia had a very small effect on linear growth and did not reduce morbidity compared
to unfortified SQ-LNS. An early increase in repeat visits indicates a need for the establish-
ment of evidence-based guidelines and caution with systematic prescribing of MMN. Future
research should be directed at understanding the mechanisms behind the lack of effect of
MMN supplementation on morbidity measures and limited effect on growth.
Trial registration
ISRCTN 73571031.
Author summary
Why was this study done?
• Multiple micronutrients (MMN) are prescribed widely in low- and middle-income
settings.
• There are currently no established evidence-based international clinical guidelines for
the use of MMN in ill children.
• Community-wide trials of MMN within a lipid-base supplement have shown improvement
in linear growth in some settings, although the effect on morbidity is underresearched.
• Our study was designed to investigate the effect of lipid-based MMN in ill children in
relation to the frequency of subsequent primary health clinic visits and growth.
What did the research do and find?
• We performed a prospective, double-blind randomised controlled trial of small-quan-
tity lipid-based MMN in ill children presenting to a rural primary healthcare clinic in
West Africa.
Micronutrient supplementation in acutely unwell Gambian children
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• We enrolled 1,100 children aged 6 months (mo) to 5 years (y).
• Children were supplemented either with the lipid-base alone or a micronutrient-
enriched lipid-based supplement for 6 wk or 12 wk.
• The trial showed no effect of small-quantity lipid-based MMN supplementation com-
pared to unfortified supplement on subsequent all-cause morbidity as assessed by clinic
visits over 6 mo, but post hoc analysis revealed a significant 43% increase in clinic pre-
sentations over the first 3 wk of supplementation.
• Despite a significant increase in children’s reported appetite, there was only a small ben-
efit on linear growth.
What do these findings mean?
• Randomised trials have so far failed to demonstrate consistent beneficial effects of
MMN supplementation (lipid-based or not) on growth and morbidity, and there is
some evidence of potentially harmful effects, likely related to iron in the supplements.
• Blanket prescribing of MMN in primary health clinics in similar settings is not sup-
ported by current evidence.
Introduction
It has been estimated that vitamin and mineral deficiencies affect more than 2,000,000,000
people worldwide. Together with other manifestations of malnutrition (fetal growth restric-
tion, stunting, and low breastfeeding rates), such deficiencies contribute to over 3 million child
deaths worldwide; approximately 45% of the total. [1]
In recognition of the fact that children in deprived populations tend to suffer from a combi-
nation of nutrient deficiencies, recent intervention programs have favoured the use of multiple
micronutrients (MMN). MMN are also widely, and often indiscriminately, prescribed in pri-
mary healthcare clinics, despite the absence of a supporting evidence base. [2]
MMN are available as liquids, dispersible tablets, micro-encapsulated powders, or embed-
ded in lipid-based nutrient supplements (LNS). Lipid-based MMN supplements may lower
the risk of overdosing, address macro- as well as micronutrient deficiencies, and can enhance
the absorption of fat-soluble vitamins.[3] Despite these potential benefits, the recently-
reported trials of community-based LNS distribution in Burkino-Faso,[4] Malawi,[5,6] Ban-
gladesh [7] and Ghana [3,8] show a limited and heterogeneous impact on growth and develop-
ment. Short-term ready-to-use therapeutic foods (RUTF) supplementation targeted at
nonmalnourished but acutely sick children also had limited efficacy and only in one of the set-
tings studied. [9,10] (S3 Text).
Because of the tight interplay between nutrition and infection [11], we reasoned that by tar-
geting ill children who would have a greater need of nutrient replenishment, clinic-based
distribution of small-quantity lipid-based nutrient supplements (SQ-LNS) might be more
effective, efficient, and easily implementable. We tested this hypothesis in a randomised
Micronutrient supplementation in acutely unwell Gambian children
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clinical trial in children presenting to a rural primary healthcare clinic in sub-Saharan Africa.
Primary outcomes were growth and morbidity, measured as repeat presentations to the clinic.
Methods
Ethics statement
Ethics approval was granted by the joint Gambian Government/Medical Research Council
(MRC) Unit The Gambia Ethics Committee (SCC1135v2, L2009.58, L2009v2) and the London
School of Hygiene and Tropical Medicine Ethics Committee (5629) (S2 Text). Community
approval to run this trial in Kiang West was given after a series of meetings between the princi-
ple investigator and community leaders in each village, including the Alkalos (village heads)
and Imams (Islamic clerics).
Study design and participants
We undertook a double-blind randomised placebo-controlled trial of a SQ-LNS in children
presenting to a primary healthcare clinic in Kiang West an isolated, rural district of The Gam-
bia. The trial was conducted to good clinical practice (GCP) standards.
Kiang West has a population of around 15,000. Rural subsistence farming is the main
livelihood, which is heavily influenced by the unimodal annual rainy season. The under-5
mortality rate is lower than the national average (45 versus 54 per 1,000 live births). [12]
The population is served by 1 main primary healthcare centre in Keneba, run by the MRC,
and 2 smaller government-run health stations. The Keneba primary healthcare clinic,
located centrally within Kiang West, provides free general healthcare to all Kiang West citi-
zens. Around 1,500 residents excluding visitors from outside Kiang West are seen at the
clinic each month.
The Keneba Electronic Medical Records System (KEMReS) was developed as an enabling
technology to capture clinical data. [12] KEMReS is linked to the Kiang West Demographic
Surveillance System (KWDSS), a database containing basic demographic data with unique
identification numbers for all residents.
All Kiang West children aged 6 to 60 months (mo) presenting with an acute illness to
the Keneba primary healthcare centre were eligible for inclusion in the study. Children
enrolled in another research study, or those with known haemoglobinopathies or severe
malnutrition were excluded. Children with severe malnutrition as defined by the World
Health Organization (WHO) [13] were treated at the MRC Keneba nutritional rehabilita-
tion centre and then became eligible for enrolment at a subsequent self-referred presenta-
tion after successful management. Children and infants called for routine child welfare
clinics, clinical follow-up appointments, and immunisations were excluded unless they
presented with an acute illness. Children were eligible for enrolment at a subsequent self-
referred presentation.
A doctor assessed all presenting children and completed an eligibility form. A trial team
member then provided information about the study to the caregiver of the child, and oral and
written consent were taken before enrolment.
All children enrolled in the trial were followed-up daily for 1 week (wk) and then fort-
nightly until the end of the 12-wk supplementation period to gather caregiver-reported mor-
bidity and compliance data. Anthropometry measurements were taken at recruitment and 6
wk, 12 wk 24 wk, and 24 mo after enrolment. Re-presentation with any illness to one of the 3
clinics in Kiang West was monitored over 6 mo after enrolment.
Micronutrient supplementation in acutely unwell Gambian children
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Randomisation and masking
Participants were randomised into 3 groups: (1) supplementation with micronutrient-fortified
SQ-LNS for 12 wk (MMN-12); (2) supplementation with micronutrient-fortified SQ-LNS for
6 wk followed by unfortified SQ-LNS for 6 wk (MMN-6); or (3) supplementation with unforti-
fied SQ-LNS for 12 wk (MMN-0). Balance with respect to date of recruitment was achieved
using block randomisation (blocks of 12). Participants were allocated their randomisation
code according to sequence of presentation.
The third, eighth, thirteenth, and subsequently every fifth child within each supplement
group were assigned to a subgroup for micronutrient status measurements at the end of the
12-wk supplementation period (measurement of haemoglobin and plasma zinc, retinol, 25
(OH) vitamin D (25(OH)D) and selenium).
Supplement jars were identical apart from their label, using 16 letters per 6-wk supplemen-
tation period to minimise bias. The code was only known to the MMN producer (Valid Inter-
national, Kenya) and an independent person. Investigators, study team members, statistician,
and participants were masked to the composition of the supplementation until after the results
of the analysis according to the preagreed statistical analysis plan were available.
Procedures
The intervention was a SQ-LNS developed in collaboration with Valid International, Nairobi,
Kenya. The SQ-LNS contained 23 micronutrients (S1 Table). Two different fortified spreads
were used, identifiable by the colour of the cap of the supplement: 1 for the age groups 6–12
mo (SQ-LNS-MMN-1) and 1 for the age group 1–5 y (SQ-LNS-MMN-2), adjusting for the dif-
ferences in Recommended Daily Allowance (RDA)/Recommended Nutrient Intake (RNI) at
different ages. SQ-LNS-MMN-0 was the lipid-based paste without added MMN.
To mimic a possible programme setting, a 14-day supply of supplement was given to the
caregiver of the enrolled children every 2 wk. The supplement was supplied in jars containing
60 g of LNS. Supplementation of the child was not observed by a study team member. Trial
members were trained in delivering clear instructions on how to supplement the children.
Caregivers were asked to administer SQ-LNS on a daily basis by mixing 4 levelled teaspoons of
supplement (equivalent to 20 g of SQ-LNS) with the child’s food. Self-reported noncompliance
was defined as any participant consuming less than 70% intended. Advice was given when to
present to the primary healthcare facility for an illness and to continue with the supplementa-
tion unless advised otherwise by a member of the medical team.
After the initial daily visits for morbidity data collection during the first wk of supplementa-
tion, a team of trained trial fieldworkers (FWs) visited each child fortnightly during the 12-wk
supplementation period, recording morbidity using data collection procedures previously
trialled in the study population. FWs also counted used supplementation jars and replenished
the supplement held by the caregiver to provide the next 14-day dose. At each visit to the
child’s family, the caregiver was interviewed to obtain information on child’s appetite, pres-
ence or absence of diarrhoea, vomiting, cough, rapid breathing, and perceived fever in the pre-
ceding 72 h. Diarrhoea was defined as 3 or more loose stools per day.
Anthropometric measures were undertaken by trained trial staff and clinic team members
using standardised methods. Two sets of anthropometric data were taken and entered into the
database. If they were the same or within the accepted error range, the first data set was used.
If the data differed, measurement had to be repeated. Quality control checks were set within
the electronic patient record system and performed according to standardised operating
procedure (S5 Text). Trial staff received repeated mini-assessments and refresher training
throughout the trial. Length or height was measured using a Harpenden Infantometer length
Micronutrient supplementation in acutely unwell Gambian children
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board (Holtain Ltd) or stadiometer (Leicester Height Measure; model MKII), respectively.
Weight was measured using digital scales (Seca, model 336; sensitivity 0.01 kg for infants or
Tanita HD-305 scale; sensitivity 0.1 kg, for older children). Mid-upper arm circumference
(MUAC) was measured using a paper measuring tape to a precision of 0.1 cm. Measures were
expressed as z-scores based on the WHO 2006 Growth Standard [14], and effects of MMN
supplementation were calculated based on internal growth reference data collected in Kiang
West Keneba clinic between 12 December 2009 and 2 June 2012. Anthropometry equipment
was checked weekly.
Children self-referred to the clinic were assessed each time by 1 of 3 medical officers using a
standardised proforma within KEMReS. [12] Based on previous data and safety concerns with
regards to iron supplementation, [15] supplementation was withheld in children presenting
with severe malaria, severe sepsis, or severe anaemia until successful management of the condi-
tion; severity was classified as requiring admission/referral to a hospital and the need for intra-
venous (IV) quinine/artesunate, IV antibiotics, and blood transfusions, respectively. All
children presenting to Keneba were treated in accordance with the Gambian/WHO clinical
guidelines. [13] Additional morbidity data on presentations at government-run health centres
in Kiang West were also collected.
Venous blood was collected at the end of the supplementation period at 12 wk in the subset
selected for micronutrient status analysis. Haemoglobin concentration was measured using an
automated haematology analyser (Medonic M-series 3-part haematology analyser [Boule Med-
ical]). Plasma was separated and stored at −70˚C. Samples were then transported to MRC
Human Nutrition Research (HNR), Cambridge, United Kingdom on dry ice and analysed for
plasma zinc and selenium using inductively coupled plasma-mass spectrometry. Plasma reti-
nol levels were analysed by high-performance liquid chromatography and plasma 25(OH)D
by a chemiluminescent assay. Plasma C-reactive protein (CRP) was measured using a com-
mercial colorimetric immunoassay, and alpha(1)-acid glycoprotein (AGP) was measured by
an immunoturbidimetric specific reaction (Sentinel Diagnostics). Zinc, selenium, retinol, and
25(OH)D levels were adjusted for CRP and AGP in the analysis.
Outcomes
Our primary outcomes were morbidity measured as presentations to a clinic in Kiang West
within 6 mo and growth at 6 mo after enrolment.
Secondary outcomes included the following: (1) caregiver-reported morbidity collected
daily for the first wk and then fortnightly during the 12-wk supplementation period; (2) repeat
presentation to clinic (separated into those diagnosed with diarrhoeal, acute respiratory,
malarial, or skin infection); (3) micronutrient status for zinc, retinol, selenium, and 25(OH)D
and haemoglobin levels at the end of supplementation; (4) caregiver-reported appetite during
supplementation; and (5) growth at 2 y after enrolment.
Any self-referred clinic visit was recorded as a potential adverse event, and a summary of
events was sent at agreed intervals to the trial and data safety monitors. Any clinic presenta-
tions with severe illness or any deaths were registered as severe adverse events, and the data
safety monitor was informed within 24 h, followed by a detailed description and assessment of
each case. Any visits to clinics outside Kiang West were recorded as part of the 2 wk FW visit.
Statistical analysis
There were no published data on the effect of nutritional intervention on repeat clinic visits in
this age group on which to base a power calculation. Prior to the introduction of KEMReS,
limited data was available on clinic presentations at MRC Keneba in patients over 3 y old and
Micronutrient supplementation in acutely unwell Gambian children
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from those residents outside the ‘core villages’ in Kiang West. [12] We originally estimated
that there were over 1,000 clinic visits for the age group 6–12 mo old and 2,000 clinic visits for
the age group 1–5 y old per y, with approximately 25% of clinic visits being repeat visits—i.e.,
return visits made by those who have already visited at least once. Estimations were made
from data available for under-3-y-old children from the 3 core villages. We estimated that 466
children per group would provide 80% power to detect a 15% reduction in repeat clinic visits
with intervention, and 252 would detect a 20% difference. We aimed to recruit 500 children
per group.
All participants, who received at least 1 dose of SQ-LNS were included in the analysis using
STATA (version 12) based on a predefined analysis plan agreed with the trial monitor (S4
Text). Children who were wrongly recruited and who did not receive any supplement were
not included in the analysis. For repeat clinic presentations, we used a negative binomial
model relating the number of clinic visits to treatment group and known predictors of clinic
visits. We included variables to reduce noise rather than remove confounding. Variables
included were treatment group, distance to the nearest health clinic, distance to the Keneba
clinic, age, weight-for-height z-scores (WHZ) at recruitment, season at recruitment, sex, and
access to transport to the clinic. The analysis of effects on growth (z-scores) referenced internal
growth data collected by KEMReS. Growth was then analysed with a mixed model, capturing
individual differences as random effects for both intercept and slope. Season, WHZ at recruit-
ment, sex, and age were included in the regression analysis as known predictors of growth.
Stunting was defined as height-for-age z-scores (HAZ) of less than −2 standard deviation (SD)
based on the WHO growth reference data. [14] The statistical analysis was extended (deviation
from the original statistical analysis plan) to assess repeat clinic presentations within the initial
3 wk of supplementation.
The trial was registered as ISRCTN 73571031 before the start of recruitment (http://www.
controlled-trials.com/).
An independent data safety monitor and an independent trial monitor assessed the study
protocol and suitability of the trial site, assessed interim data, and assessed all serious adverse
events (SAE). They also approved the statistical analysis plan (S4 Text) prior to the blinded
analysis. The trial was terminated at the end of the prespecified 30-mo recruitment period.
This study is reported as per CONsolidated Standards of Reporting Trials (CONSORT) guide-
lines (S1 CONSORT Checklist).
Results
Between 12 December 2009 and 3 June 2011, 2,743 children presenting to the primary
care clinic were assessed for eligibility, of whom 1,642 children were either not eligible, the
research clinician was unable to perform trial assessment, or the caregiver did not give con-
sent. The remaining 1,101 children entered the trial (Fig 1). Sixteen children were recruited
but did not fulfil the inclusion criteria and hence were withdrawn and removed from the
analysis. After 12 wk, 1,051 (96.8%) children remained under follow-up and 1,020 (94.0%)
after 24 wk.
The 3 groups were similar at baseline for a range of indicators including distance to the
health facility and crowding (Table 1). Disease patterns at initial presentation were similar
across treatment groups (Table 1).
Overall mean compliance when including those lost to follow-up or withdrawn was 85%
(87% excluding those lost to follow-up) and was similar across intervention arms (Table 2).
We did not observe any reduction in consumption over time and sharing of supplement as
reported by the caregiver was minimal (<1%).
Micronutrient supplementation in acutely unwell Gambian children
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Repeat clinic visits
Overall, there were 2,514 return clinic visits within 24 wk of recruitment. Of those, 2,224 visits
(89%) were included in subsequent analysis according to the statistical analysis plan (S4 Text).
Median re-presentation was 2 (IQR 0–4, range 0–15). A quarter of the children never pre-
sented again to a clinic within Kiang West during the 24-wk follow-up period. There was no
significant effect of supplementation on repeat visits overall (adjusted incidence rate ratio
[IRR] 1.04 [95% CI: 0.94, 1.15]) and no difference between the 2 fortified SQ-LNS groups
(Table 3). Similarly, there was no significant effect on re-presentation when separated into
respiratory, diarrhoeal, and malarial disease, and skin infections or when clinic visits with
severe illness were analysed separately.
During post hoc analysis, it became apparent that the effect of MMN on re-presentations
became significant when only looking at the initial period after recruitment (initial 3 wk)
(Table 3). MMN supplementation significantly increased, rather than decreased, clinic return
presentations (adjusted IRR 1.43; 95% CI: 1.07, 1.92; p = 0.016; risk difference = 8/100). Respi-
ratory infections were increased by 52%, although the effect was only borderline significant
(adjusted IRR 1.52; 95% CI: 1.01, 2.30; p = 0.046, risk difference = 5/100). There was no signifi-
cant increase in severe presentation seen within the first 3 wk (adjusted IRR 1.80; 95% CI: 0.58,
1.60; p = 0.307). Severe adverse events overall were also not different between intervention
groups (S2 Table).
Fig 1. CONSORT flow chart of the trial. KW, Kiang West; MMN, multiple micronutrients.
https://doi.org/10.1371/journal.pmed.1002377.g001
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Growth
Stunting was prevalent in 25.4% (276/1,085) of our study population at baseline. Similarly to
usual trends among infants and young children in this population, HAZ declined across all
intervention arms over the 6-mo follow-up (Table 4). However, the decrease was less marked
in the MMN-12 group, with a benefit of 0.084 standard deviations (95% CI: 0.005, 0.168) at 24
wk (Table 4). There was no evidence at 24 wk, however, that MMN-12 out-performed MMN-
6 (95% CI: −0.118, 0.084). No statistically significant effects on z-scores for weight, MUAC, or
skin-fold thickness were detected. Anthropometric measures were statistically significantly
affected by season, and all analyses were adjusted for season as specified in the statistical analy-
sis plan. (S4 Text).
Table 1. Baseline characteristics according to randomised groups.
MMN-0
(N = 361)
MMN-6
(N = 362)
MMN-12
(N = 362)
Socio-demographic factors
Mean age in y 2.1 (1.3) 2.1 (1.3) 2.1 (1.3)
Male 54% (193/361) 55% (198/362) 50% (180/362)
Mandinka ethnicity 84% (303/361) 86% (312/362) 85% (307/362)
Mean distance to Keneba clinic (km) 10.1 (8.3) 9.4 (7.9) 9.9 (8.2)
Mean distance to closest health centre (km) 7.4 (5.6) 7.1 (5.5) 7.3 (5.6)
Home village off a main road 14% (50/361) 12% (45/362) 11% (38/362)
Dead sibling in the family 24% (86/361) 25% (90/362) 22% (79/362)
Mean number of paternal siblings 7.5 (5.8) (n = 334) 7.0 (5.9) (n = 339) 7.3 (6.0) (n = 336)
Mean number of maternal siblings 4.1 (2.6) (n = 360) 4.0 (2.8) (n = 359) 4.1 (2.5) (n = 355)
Mean maternal birth order 4.5 (2.6) (n = 360) 4.4 (2.8) (n = 359) 4.4 (2.4) (n = 355)
Mean number of co-wives 1.7 (0.9) (n = 328) 1.7 (0.9) (n = 331) 1.7 (0.9) (n = 326)
Mean mother’s age 31.0 (6.8) (n = 357) 31.2 (7.4) (n = 354) 31.5 (7.2) (n = 354)
Mothers without education in English school 84% (302/360) 86% (310/362) 83% (300/361)
Mother dead 0.8% (3/361) 0.3% (1/362) 0.6% (2/362)
Child not living with mother 21% (75/361) 16% (57/362) 18% (65/362)
Parents divorced 11% (39/361) 10% (36/362) 13% (46/362)
Presenting disease diagnoses at recruitment
Total number of diagnoses given 461 449 476
Infectious disease diagnosis* 91% (419/461) 92% (414/449) 91% (431/476)
Respiratory infection diagnosis 42% (193/461) 49% (220/449) 46% (218/476)
Diarrhoeal infection diagnosis 24% (112/461) 21% (94/449) 22% (103/476)
Malaria 0.2% (1/461) 0.5% (2/449) 0.4% (2/476)
Skin infection 17% (78/461) 13% (56/449) 13% (62/476)
Other infection 8% (35/461) 9% (42/449) 10% (46/476)
Injury 1% (5/461) 2% (7/449) 04% (2/476)
Nutrition related* 0.2% (1/461) 1% (5/449) 1% (1/476)
Other diagnoses 8% (36/461) 5% (23/449) 8% (39/476)
Data are N, % (n/N) or mean (SD). The number of participants with data available is given in brackets if less than the participant number per intervention
group.
*Definition in statistical analysis in appendix. MMN, multiple micronutrients; MMN-0, supplementation with unfortified SQ-LNS for 12 wk; MMN-6,
supplementation with micronutrient-fortified SQ-LNS for 6 wk followed by unfortified SQ-LNS for 6 wk; MMN-12, supplementation with micronutrient-fortified
SQ-LNS for 12 wk.
https://doi.org/10.1371/journal.pmed.1002377.t001
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Micronutrient status
Table 5 shows the means of haemoglobin and plasma retinol, 25(OH)D, selenium, and zinc
levels and effect sizes after 12 wk of supplementation. Mean haemoglobin concentrations
were 0.53 g/dl lower in the unfortified SQ-LNS group compared to both fortified groups com-
bined with the regression analysis showing an adjusted effect size of MMN supplementation of
0.44 g/dl (95% CI: 0.03, 0.85; p = 0.037). There was no difference between the MMN-6 and
MMN12 groups (−0.02; 95% CI: −0.02, 0.93; p = 0.923). The proportion of anaemic children
(Hb< 11.0 g/dL) was lower in the MMN groups (MMN-0 46%, MMN-6 36%, MMN-12 33%).
Adjusted regression analysis showed a 12% (95% CI: 3%, 22%; p = 0.011) change in plasma
25(OH)D levels with MMN supplementation relative to unfortified SQ-LNS. The effect was
dose-dependent with a significant difference between MMN-6 and MMN-12 (p = 0.027).
Overall, 30% (59/195) of the children tested were zinc deficient (plasma zinc<647μg/l), 22%
(42/194) had mild vitamin A deficiency (plasma retinol <0.70 μmol/l), and 14% (27/195)
Table 2. Compliance overall and by intervention group.
Overall MMN-0
group
MMN-6
group
MMN-12
group
p
value*
Number of participants at recruitment 1,101 368 367 366
Number of participants after exclusions of those wrongly recruited
(entered into analysis)
1,085 361 362 362
Mean percentage of compliance including those lost to
withdrawal/lost to follow-up (SD, median)
85% (16%) 85% (16%) 86% (14%) 85% (17%) 0.299
Number of withdrawals/lost to follow-up during
supplementation
34 17 8 9 0.107
Details of withdrawals/lost to follow-ups Travel 5 4 1 0
Medical 3 2 0 1
Refusal 1 0 1 0
Consent
withdrawn
3 0 2 1
Migration 19 9 3 7
Died 3 2 1 0
Number of participants after excluding those lost to follow-up 1,051 344 354 353
Mean percentage of compliance excluding those lost to
withdrawal/lost to follow-up (SD, median)
87% (12%) 87% (11%) 87% (12%) 87% (13%) 0.968
Number of noncompliant participants 102/1,051
(10%)
31/344
(9%)
31/354
(9%)
40/353
(11%)
0.445
Number of follow-ups with no information due to travel of the
participant
110/6,103
(2%)
30/1,992
(2%)
39/2,059
(2%)
41/2,052
(2%)
0.465
Number of incomplete forms 16/5,993
(0.3%)
4/1,962
(0.2%)
6/2,020
(0.3%)
6/2,011
(0.3%)
0.804
Number of follow-ups indicating vomiting with supplementation 13/5,977
(0.2%)
6/1,958
(0.3%)
4/2,014
(0.2%)
3/2,005
(0.2%)
0.556
Number of follow-ups indicating refusal of supplement 96/5,977
(1.6%)
28/1,958
(1.4%)
33/2,014
(1.6%)
35/2,005
(1.7%)
0.725
Number of follow-ups indicating sharing of supplement 7/5,977
(0.1%)
2/1,958
(0.1%)
1/2,014
(0.1%)
4/2,005
(0.2%)
0.411
* p values shown here are derived from ANOVA or Pearson’s chi-squared analysis comparing the 3 intervention groups. MMN, multiple micronutrients;
MMN-0, supplementation with unfortified SQ-LNS for 12 wk; MMN-6, supplementation with micronutrient-fortified SQ-LNS for 6 wk followed by unfortified
SQ-LNS for 6 wk; MMN-12, supplementation with micronutrient-fortified SQ-LNS for 12 wk.
https://doi.org/10.1371/journal.pmed.1002377.t002
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had plasma selenium levels below the recommended level for maximal activity of glutathione
peroxidase and selenoprotein P (plasma selenium concentration >1.2 μmol). MMN supple-
mentation did detectably not improve the status of plasma zinc, selenium, and retinol among
study participants (Table 5).
Table 5. Haematological outcomes after 12 wk of supplementation.
MMN-0 group MMN-6 group MMN-12 group MMN combined Effect size p value*
(unadjusted)
p value**
(adjusted)
Haemoglobin (g/dl)
N 59 69 60
Mean 11.06 (10.75–11.37) 11.58 (11.25–11.90) 11.48 (11.17–11.81) 0.44 g/dl/12 wk (95% CI 0.03,
0.85)
0.018 0.034
% anaemic (Hb < 11 g/dl) 46% (33%–59%) 36% (25%–48%) 33% (21%–45%)
% anaemic (Hb < 10 g/dl) 14% (7%–25%) 7% (3%–16%) 8% (4%–19%)
Retinol (μmol/l)
N 61 72 61
Mean 0.91 (0.84–0.98) 0.92 (0.85–0.98) 0.92 (0.86–0.98) 0.05 μmol/l/12 wk (95% CI
−0.03, 0.12)
0.91 0.231
% deficiency
(Retinol < 0.7 μmol/l)
18% (8%–28%) 26% (16%–37%) 20% (10%–30%)
25(OH) Vitamin D (nmol/l)
N 61 73 61
Mean 66.25 (61.25–71.25) 71.92 (67.34–76.51) 79.90 (73.56–86.24) 12%/12 wk (95% CI 3, 22) 0.003 0.011§
% mild deficiency (<75 nmol/l) 77% (67%–88%) 66% (55%–77%) 49% (37%–62%)
% moderate deficiency (<50
nmol/l)
16% (6%–23%) 14% (6%–22%) 6% (1%–13%)
Zinc (μg/l)
N 62 73 60
Mean 727.59 (694.46–
760.72)
724.56 (692.53–
756.59)
768.86 (713.06–
824.67)
3%/12 wk (95% CI −3, 10) 0.50 0.31
% deficiency (<647 μg/l) 27% (16%–39%) 30% (20%–41%) 33% (21%–45%)
Selenium (μg/l)
N 62 73 60
Mean 100.16 (94.08–
106.23)
97.52 (92.51–
102.53)
97.73 (93.02–
102.46)
−2%/12 wk (95% CI −9, 5) 0.44 0.63
Percentage deficiency
(79 μg/l)
13% (4%–21%) 15% (7%–23%) 13% (5%–22%)
CRP (mg/l)
N 54 68 56
Mean 4.2 (2.8–5.6) 5.6 (3.4–7.9) 7.8 (1.8–13.8)
AGP (g/l)
N 54 68 56
Mean 0.99 (0.89–1.08) 0.93 (0.85–1.01) 0.94 (0.86–1.02)
Data are means or proportions (95% CI).
*unadjusted p values for regression analysis of effect of MMN overall (both treatment groups combined).
**p values for regression analysis of effect of MMN overall (both treatment groups combined) adjusted for age, sex, season, weight-for-height z-scores at
recruitment, CRP, and AGP.
§The difference between the 6- and 12-wk MMN group was also statistically significantly different, p = 0.027. AGP, alpha(1)-acid glycoprotein; CRP, C-
reactive protein; MMN, multiple micronutrient; MMN-0, supplementation with unfortified SQ-LNS for 12 wk; MMN-6, supplementation with micronutrient-
fortified SQ-LNS for 6 wk followed by unfortified SQ-LNS for 6 wk; MMN-12, supplementation with micronutrient-fortified SQ-LNS for 12 wk; wk, week.
https://doi.org/10.1371/journal.pmed.1002377.t005
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Actively-surveyed morbidity
Reported morbidity (daily over the first 7 days postrecruitment and fortnightly thereafter until
the end of supplementation) showed that symptom scores and symptom resolution over the
first wk of supplementation was not different across intervention groups (Table 6, Fig 2). Simi-
larly, symptom scores overall and separated for respiratory and diarrhoeal symptoms were not
statistically different during the supplementation period (Table 6).
Appetite
Appetite was recorded daily for the first week after recruitment and fortnightly thereafter until
the end of active intervention at 12 wk. Supplemented participants were 8% more likely to
show an improved appetite within the first week (hazard ratio: 1.08; 95% CI: 1.01, 1.15;
p = 0.018) (S2 Table). MMN supplementation also significantly improved appetite scores over-
all during the 12-wk supplementation period (0.29 score/12 wk; 95% CI: 0.07, 0.53; p = 0.010).
The effect was even more pronounced during the first 6 wk after enrolment (0.40 score/6 wk;
95% CI: 0.12, 0.67; p = 0.005).
Discussion
To our knowledge, this is the first randomised controlled trial to investigate the effects of
micronutrient-fortified versus unfortified SQ-LNS in children presenting to a primary health-
care facility. We studied a well-described population with a high rate of stunting, little migra-
tion, and low loss to follow-up. Reported compliance was probably the best that can be
achieved when supplementation is not directly observed [16] and exceeded what would occur
in programmatic settings.
There was no reduction in repeat clinic attendances and very minimal benefit to growth
despite an enhancement of appetite with added MMN. The suggestion, upon secondary analy-
sis, that morbidity was elevated by micronutrients is potentially concerning.
Point of care provision of SQ-LNS-MMN compared to unfortified SQ-LNS did not reduce
return clinic presentations within a 6-mo period despite the high compliance. Neither was
there an effect on the duration of the clinical symptoms associated with the initial presentation.
However, appetite improved appreciably with MMN. In the primary analysis, there was a non-
significant trend to increased morbidity over the entire 6-mo follow-up. The incidence of
severe illness during follow-up did not differ between the groups, although this was based on
few events. However, post hoc analysis revealed a 43% increase in total return visits to clinic
(95% CI 7%–92%) within the first 3 wk of intervention in the 2 SQ-LNS-MMN groups. There
are several grounds to suspect that the 12 mg per day iron in the MMN could be responsible
for this effect. [17] Iron lies at the centre of a host–pathogen battle for nutritional resource
[18,19], and there are numerous instances in which iron is implicated as causing iatrogenic
disease, including malaria, diarrhoea, and pneumonia. [20–22] Iron supplementation modifies
the gut flora by enhancing potentially pathogenic organisms in the place of beneficial lactoba-
cilli and bifidobacteria, and this increases inflammation in the gut. [20] These findings pose
several challenges as to how best to combat iron deficiency in environmentally-challenged
populations and imply that infection control must be prioritised.
There is an extensive, though heterogeneous, evidence base on the effects of single micro-
nutrient interventions (mainly vitamins A and D, zinc, and iron) on morbidity outcomes, but
the effect of MMN supplementation on child mortality and morbidity is underresearched. [22]
Morbidity is often a secondary outcome measure [9,10], and data from previous MMN supple-
mentation or fortification trials have shown variable outcomes in terms of their effect on mor-
bidity, some suggesting improvements, [4] although many showing no detectable benefit on
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illness [9,22,23] despite showing improvement in iron status and anaemia. [21] Some previous
studies have also suggested possible increases in certain morbidity outcomes, even with short-
term supplementation. [10,21,24]
Receiving SQ-LNS with MMN had a very small benefit on growth. It reduced the typical
decline in linear growth seen in this population by 0.084 z-score compared to unfortified
SQ-LNS—equivalent to 2–5 mm depending on the age of the children with debatable clinical
relevance. Twelve-week supplementation did not show significant advantage over a 6-wk
supplementation period. The duration of supplementation was shorter than other SQ-LNS
studies [4,6] although similar to some MMN supplementation trials. [25] Shorter courses of
supplementation are associated with better compliance [26] and are more easily introduced in
practice.
When we initiated our study, there was considerable optimism that lipid-based micronutri-
ent supplements would have a significant impact on community-based nutritional intervention,
and several trials coordinated by the International Lipid-Based Nutrient Supplements (iLiNS)
consortium were in progress (www.ilins.org). [27] Some of these trials have now reported, with
variable results. In Malawi, provision of SQ-LNS to mothers during pregnancy and for 6 mo
postpartum and then to infants after 6 mo achieved no differential impact on growth by 18 mo.
[6] In all groups, length-for-age deteriorated by approximately 0.4 z-score between 6 mo and 18
mo, and 35% of children were stunted at 18 mo. In a cluster-randomised trial in Burkino Faso,
children receiving SQ-LNS with various doses of zinc (intervention cohorts) were 7 mm longer
at 18 mo (equivalent to 0.25 SD), but the intervention groups also received weekly morbidity
surveillance and treatment, which was not offered to the nonintervention cohorts. [4] The
Fig 2. Means of symptom scores and proportion of types of symptoms reported at recruitment and over the
following 6 days.
https://doi.org/10.1371/journal.pmed.1002377.g002
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prevalence of stunting increased between 9 mo and 18 mo in both groups but significantly less
so in the intervention cohorts (reaching 29% in intervention cohorts and 39% in the noninter-
vention cohorts, p< 0.001). A prior study in Ghana compared an earlier version of SQ-LNS
(Nutributter) to crushable multiple-micronutrient tablets and encapsulated multiple-micronu-
trient powders (Sprinkles ©). [3] The baseline prevalence of stunting was low at 12%. Between 6
mo and 12 mo, the Nutributter significantly attenuated the decline in length-for-age by 0.18 z-
score compared to the other 2 groups. A more recent supplementation trial in Ghana with
SQ-LNS during pregnancy and for infants from 6 mo to 18 mo old led to a significantly greater
length-for-age z-scores (LAZ) at 18 mo old compared with standard iron and folic acid (IFA)
during pregnancy and placebo postpartum or MMN during pregnancy and lactation (LAZ:
LNS −0.69; IFA −0.87, p = 0.006; MMN: −0.91, p = 0.009). [8] Similarly, a recent cluster-rando-
mised effectiveness trial in Bangladesh providing LNS to women during pregnancy and 6 mo
postpartum and to the infants from 6 mo to 24 mo old resulted in an increased LAZ (+0.13,
p = 0.022) compared with providing IFA to mothers and MMN to children. [7] None of the
SQ-LNS trials compared fortified versus nonfortified SQ-LNS.
Short-term supplementation with RUTF for 2 wk to nonmalnourished and moderately mal-
nourished children in Nigeria during recovery from malaria, diarrhoea, or LRTI did not reduce
the incidence of malnutrition over a 24-wk period compared to no supplement [10], whereas a
33.3% reduction was seen in nonmalnourished children in Uganda. [9] Discrepancy between
the 2 studies may be related to the much lower incidence of malnutrition and infectious disease
burden in Uganda. Micronutrient status was not assessed as part of either of the trials.
In common with most other MMN trials in low-income settings, we achieved a small but
significant improvement in haemoglobin levels (+0.44 g/dl), but after 12 wk intervention, 33%
of the children remained anemic (46% in the unfortified group). Some of the remaining anae-
mia might have been related to nonnutritional factors. It has also been suggested that for popu-
lations with African ancestry, lower thresholds for the diagnosis of anaemia may be more
appropriate (Table 5 showing percentage of anaemic children for haemoglobin cutoff <11.0
g/dL and<10.0 g/dL). [28]
There was a measurable, dose-dependent improvement in vitamin D status (+12%) but not
in vitamin A, zinc, or selenium status. Reasons for the lack in difference for vitamin A, zinc,
and selenium may be related to a suboptimal amount contained in the supplement, poor
absorption, homeostatic control mechanisms, and/or adequate levels in the study population
(only 18%, 27%, and 13% were deficient in the unfortified group for vitamin A, zinc, or sele-
nium, respectively) (Table 6).
We acknowledge several limitations when considering our results. Supplementation was
not directly observed, and although recorded compliance was similar between groups and
sharing was not reported, this cannot be guaranteed. The main outcome measure of morbidity,
i.e., clinic re-presentation, is significantly influenced by distance from the home village to the
health centre and families’ access to transport. [29] However, regression analyses were adjusted
for distance and access to a main road. Morbidity recorded during supplementation was based
on caregiver’s recall only. However, this was a randomised trial, and women were blinded to
the intervention; subjectivity in morbidity reports should have influenced all groups equally
but may have diluted our ability to detect an effect (negative or positive). Acceptance of the
supplement in the population was good based on acceptability studies prior to the trial. The
LNS paste may have replaced some of the daily intake in the younger age group hence diluting
the effect of LNS combined with MMN. However, impact of SQ-LNS on feeding practices
seems to be limited. [30, 31] The different micronutrient concentrations within the supple-
ments for infants and children may have had a different impact on the outcomes measured;
although, due to low numbers within each group, we do not have the power to confirm these
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suggestions (Fig 1). The number of participants recruited was lower than intended based on a
priori power calculation (n = 1,101 versus n = 1,500). With the number of study participants
enrolled, we would only detect a difference of 18% (compared to the initial 15% target) in the
main outcome of clinic representations with 80% and 5% significance levels. Given that the
secondary outcomes of reported morbidity and severe adverse events did not differ between
intervention groups, the authors cannot rule out that the small difference in clinic re-presenta-
tions (when adjusted and using combined groups) may be a chance finding.
Our trial had many strengths. It was appropriately randomised and blinded, and loss to fol-
low-up and missing data were minimal compared to other trials. In particular, the targeting of
children presenting to a rural clinic had the potential to self-select a subpopulation at greatest
need and to enhance recovery from the presenting condition. If it had proved effective, such a
strategy would be more cost-effective and much easier to implement in terms of supply and
distribution than population-wide mass administration.
We conclude that prescribing micronutrients via SQ-LNS to acutely ill nonmalnourished
and mild-to-moderately malnourished children presenting at a primary care clinic in rural
Gambia had only a minimal effect on growth compared to unfortified SQ-LNS. Micronutrient
supplementation also did not reduce morbidity, and evidence for an early increase in repeat
visits indicates that caution is warranted when prescribing MMN in a primary care setting,
particularly if they include iron. It is highly likely that a combination of recurrent infection,
persistent gastrointestinal enteropathy, and chronic inflammation are major factors in limiting
the response to nutritional intervention.
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